Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
AlphaOnco currently maintains 7 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 7 pending office actions are distributed among 7 distinct examiners across 6 distinct art units. VARGAS MONTALVO, DIXOMARA is the busiest examiner with 1 busiest examiner pending action. The 6 distinct art units indicate the technical variety within the company's biotechnology filings.
With 7 distinct examiners for the 7 pending office actions, the workload is perfectly distributed. This means that every pending office action is being reviewed by a different individual, requiring the company to navigate 7 different examiner styles. The 1 busiest examiner pending action assigned to VARGAS MONTALVO, DIXOMARA represents a portion of the 7 pending office actions. Practitioners should focus on the specific preferences of each examiner to ensure successful outcomes.
The 6 distinct art units suggest that the portfolio touches on several specialized groups within the USPTO. Managing 7 pending office actions across these units requires an understanding of the specific technical standards applied by each group. Because the 7 distinct examiners are spread across 6 distinct art units, there is likely some concentration of technical focus within certain units. This structure requires a prosecution strategy that accounts for both individual examiner preferences and art unit trends.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VARGAS MONTALVO, DIXOMARA | 1 | 92.6% | +8.4% |
| LACLAIR, LOGAN EDWARD | 1 | 78.2% | +22.2% |
| SHOMER, ISAAC | 1 | 63.2% | +30.4% |
| PATEL, RONAK C | 1 | 51.2% | +56.4% |
| YANG, JIE | 1 | 62.6% | +19.4% |
| ROGERS, JAMES WILLIAM | 1 | 46.2% | +22.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19403345 | INTERFERENCE SYSTEM COMPRISING AT LEAST TWO SOURCES OF RADIATION EMITTING TWO BEAMS OF RADIATION INTERFERING IN A BODY PART OR REGION TO BE TREATED AND AT LEAST ONE NANOPARTICLE | VARGAS MONTALVO, DIXOMARA | — |
| 18340297 | CELLULAR PRODUCTION OF PURE IRON OXIDE NANOPARTICLES | YANG, JIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17245504 | PARTICLE COMPRISING AT LEAST ONE FERRIMAGNETIC OR FERROMAGNETIC IRON OXIDE NANOPARTICLE ASSOCIATED WITH AT LEAST ONE COMPOUND FOR MEDICAL OR COSMETIC USE | ROGERS, JAMES WILLIAM | 25d overdue |
| 18895634 | METHOD FOR REMOVING IMPURITIES FROM NANOPARTICLES | LACLAIR, LOGAN EDWARD | — |
| 18422687 | NANOPARTICLES SEQUENTIALLY EXPOSED TO LOW INTENSITY ACOUSTIC WAVES FOR MEDICAL OR COSMETIC APPLICATIONS | SHOMER, ISAAC | — |
| 18509909 | IRON OXIDE NANOPARTICLES COMPRISING TWO CENTERS OF ACTIVITIES OR FREE RADICAL CAPTURE/PRODUCTION FOR AN ENHANCED ACTIVITY AND COMBINING SPATIAL AND TEMPORAL SEQUENCES OF IRRADIATION USING THE NANOPARTICLES FOR AN IMPROVED TREATMENT OF DISEASES | PATEL, RONAK C | — |
| 18340297 | CELLULAR PRODUCTION OF PURE IRON OXIDE NANOPARTICLES | YANG, JIE | — |
| Art Unit | Apps |
|---|---|
| 3798 | 1 |
| 1612 | 1 |
| 1737 | 1 |
| 1734 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19403345 | INTERFERENCE SYSTEM COMPRISING AT LEAST TWO SOURCES OF RADIATION EMITTING TWO BEAMS OF RADIATION INTERFERING IN A BODY PART OR REGION TO BE TREATED AND AT LEAST ONE NANOPARTICLE | VARGAS MONTALVO, DIXOMARA | 3798 | §102§112 | Non-Final OA | — | Pending | Nov 28, 2025 |
| 18895634 | METHOD FOR REMOVING IMPURITIES FROM NANOPARTICLES | LACLAIR, LOGAN EDWARD | — | §102§112DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18422687 | NANOPARTICLES SEQUENTIALLY EXPOSED TO LOW INTENSITY ACOUSTIC WAVES FOR MEDICAL OR COSMETIC APPLICATIONS | SHOMER, ISAAC | 1612 | §103§112DP | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18509909 | IRON OXIDE NANOPARTICLES COMPRISING TWO CENTERS OF ACTIVITIES OR FREE RADICAL CAPTURE/PRODUCTION FOR AN ENHANCED ACTIVITY AND COMBINING SPATIAL AND TEMPORAL SEQUENCES OF IRRADIATION USING THE NANOPARTICLES FOR AN IMPROVED TREATMENT OF DISEASES | PATEL, RONAK C | 1737 | §103 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18340297 | CELLULAR PRODUCTION OF PURE IRON OXIDE NANOPARTICLES | YANG, JIE | 1734 | §103§112 | Non-Final OA | — | Pending | Jun 23, 2023 |
| 17245504 | PARTICLE COMPRISING AT LEAST ONE FERRIMAGNETIC OR FERROMAGNETIC IRON OXIDE NANOPARTICLE ASSOCIATED WITH AT LEAST ONE COMPOUND FOR MEDICAL OR COSMETIC USE | ROGERS, JAMES WILLIAM | 1618 | §103 | Final Rejection | 25d overdue | Pending | Apr 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial